Daniel Joseph OConnell - 21 Jan 2026 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
Chief Executive Officer, Director
Signature
/s/ Derek Meisner, Attorney-in-Fact
Issuer symbol
ABOS
Transactions as of
21 Jan 2026
Net transactions value
-$21,993
Form type
4
Filing time
23 Jan 2026, 18:10:48 UTC
Previous filing
21 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
OConnell Daniel Joseph Chief Executive Officer, Director C/O ACUMEN PHARMACEUTICALS, INC., 1210-1220 WASHINGTON STREET, SUITE 210, NEWTON /s/ Derek Meisner, Attorney-in-Fact 23 Jan 2026 0001865136

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABOS Common Stock Sale $16,927 -9,346 -1% $1.81 883,964 21 Jan 2026 Direct F1, F2
transaction ABOS Common Stock Sale $5,066 -2,689 -0.3% $1.88 881,275 22 Jan 2026 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2024.
F2 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7600 to $1.8800. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.8700 to $1.9000. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.